Kelan Medicine
珂阑医药
Kelan Medicine (珂阑医药) is a Shanghai-based biotech startup developing innovative drugs targeting cholesterol metabolism and related metabolic diseases. Founded in 2021 in Zhangjiang Hi-Tech Park, the company has raised two oversubscribed funding rounds exceeding 100 million RMB each: a Series A led by Gaorong Ventures in 2023, followed by an A+ round led by SDIC Venture Capital in early 2025 with continued investment from AstraZeneca's China healthcare fund . In 2023, Kelan also entered a three-year R&D collaboration with AstraZeneca focused on hypercholesterolemia and metabolic disease drug development.
AI-generated — may contain errors, please verify.
Coverage
Rongbao | Generative AI and medical device companies close new funding rounds, setting domestic records in their respective sectors
The Power of Aspiration.
高榕创投·Kailan Pharma Closes Oversubscribed A+ Round of Over 100 Million RMB to Advance Cholesterol Metabolism Drug R&D
Striving to provide alternative treatment options for patients with metabolic diseases.
高榕创投·Chip companies, surgical robots, and consumer tech brands close new funding rounds | Rongbao · June
Notable developments to watch in June.
高榕创投·New drug development, energy storage, computing, and semiconductors see breakthrough innovations: homegrown R&D, world-first technologies, and AI-driven advances
Constantly creating new possibilities.
高榕创投·Kailan Pharma Closes Oversubscribed Series A Financing of Over 100 Million RMB to Advance Innovative Drug Development in Cholesterol Metabolism
Gaorong Ventures led the round.
高榕创投·
